A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
Status: | Completed |
---|---|
Conditions: | Hepatitis, Hepatitis, Hepatitis |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/6/2019 |
Start Date: | March 28, 2017 |
End Date: | June 5, 2018 |
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)
This was a Phase 3b, open-label, non-randomized, multicenter study to evaluate the efficacy
and safety of glecaprevir/pibrentasvir (GLE/PIB) in participants with chronic hepatitis C
virus (HCV) genotype (GT) 1 - 6 infection without liver cirrhosis or with compensated liver
cirrhosis and with chronic renal impairment in participants who were either HCV
treatment-naïve (TN) or prior treatment-experienced (TE) with interferon (IFN) or pegylated
interferon (PegIFN) with or without ribavirin (RBV), or sofosbuvir (SOF) plus RBV with or
without pegIFN.
and safety of glecaprevir/pibrentasvir (GLE/PIB) in participants with chronic hepatitis C
virus (HCV) genotype (GT) 1 - 6 infection without liver cirrhosis or with compensated liver
cirrhosis and with chronic renal impairment in participants who were either HCV
treatment-naïve (TN) or prior treatment-experienced (TE) with interferon (IFN) or pegylated
interferon (PegIFN) with or without ribavirin (RBV), or sofosbuvir (SOF) plus RBV with or
without pegIFN.
The study included a 42-day screening period, a treatment period of either 8, 12, or 16
weeks, and a 24-week post-treatment period. The duration of treatment was determined by
product labeling. Participants received glecaprevir/pibrentasvir (GLE/PIB) 300 mg/120 mg once
daily. Participants who completed or prematurely discontinued the treatment period were
followed for 24 weeks after their last dose of study drug to monitor safety, hepatitis C
virus ribonucleic acid (HCV RNA), and the emergence and persistence of viral substitutions.
weeks, and a 24-week post-treatment period. The duration of treatment was determined by
product labeling. Participants received glecaprevir/pibrentasvir (GLE/PIB) 300 mg/120 mg once
daily. Participants who completed or prematurely discontinued the treatment period were
followed for 24 weeks after their last dose of study drug to monitor safety, hepatitis C
virus ribonucleic acid (HCV RNA), and the emergence and persistence of viral substitutions.
Inclusion Criteria:
- Male or female (of non-childbearing potential or using allowed contraceptive methods)
at least 18 years of age time of Screening
- Participant had a positive anti-hepatitis C virus (HCV) antibody (Ab) and plasma HCV
ribonucleic acid (RNA) greater than or equal to 1000 IU/mL at the Screening Visit.
- Participant had an estimated glomerular filtration rate (eGFR) less than 45
mL/min/1.73 m^2 as estimated by the Modification of Diet in Renal Disease (MDRD)
method at Screening according to the following formula: eGFR (mL/min/1.73 m^2 ) = 175
× (Serum Creatinine) ^-1.154 × Age^-0.203 × (0.742 if female) × (1.212 if black), or
were dialysis dependent. Subjects requiring dialysis had to have been receiving
dialysis for at least 1 month prior to enrollment, and may have been on hemodialysis
or peritoneal dialysis.
- Cirrhotic participants only: absence of hepatocellular carcinoma (HCC) as indicated by
a negative ultrasound, computed tomography (CT) scan, or magnetic resonance imaging
(MRI) within 3 months prior to Screening or a negative ultrasound at Screening.
Participants who had an ultrasound with results suspicious of HCC followed by a
subsequent negative CT or MRI of the liver were eligible for the study.
Exclusion Criteria:
- Female participants who were pregnant, breastfeeding, or were considering becoming
pregnant during the study or for approximately 30 days after the last dose of study
drug
- Current hepatitis B virus (HBV) or human immunodeficiency virus (HIV) infection on
screening tests, defined as:
- Positive test result at Screening for hepatitis B surface antigen (HBsAg), or;
- HBV deoxyribonucleic acid (DNA) greater than lower limit of quantification (LLOQ) in
participants with isolated positive hepatitis B core antibody (HBcAb), (i.e., negative
HBsAg and Anti-HBsAg), or;
- Positive anti-HIV antibody (Ab).
- Any current or historical clinical evidence of decompensated cirrhosis, including any
current or past evidence of Child-Pugh B or C classification, hepatic encephalopathy
or variceal bleeding; radiographic evidence of small ascites; or prior or current
empiric use of lactulose/rifaximin for neurologic indications. Prophylactic use of
beta blockers was not exclusionary.
- Clinical history of acute renal failure in the 3 months prior to Screening
- History of severe, life-threatening, or other significant sensitivity to any
excipients of the study drugs
- Clinically significant abnormalities or co-morbidities, or recent (within 6 months
prior to study drug administration) alcohol or drug abuse that could preclude
adherence to the protocol in the opinion of the investigator
- Receipt of any investigational or commercially available direct acting anti-HCV agents
other than sofosbuvir
We found this trial at
12
sites
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials
